{"prompt": "['MC1575', 'Mayo Clinic Cancer Center', 'Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma', 'Study Chairs:', 'Ashish V Chintakuntlawar MBBS PhD', 'Keith C Bible MD PhD', 'Mayo Clinic', '200 First Street SW', 'Rochester MN 55905', '507/284-2511', 'Study Cochairs:', 'Statistician:', 'NStudy contributor(s) not responsible for patient care', 'Drug Availability', 'Drug Company Supplied: lenvatinib (IND #133006 - EXEMPT)', 'Document History', '(Effective Date)', 'Activation', '31May2017', 'MCCC Addl', '31Aug2017', 'MCCC Amendment 2', '18Sep2018', 'Protocol Version Date:16Aug2018']['MC1575', '2', 'Amendment 2', 'Protocol Resources', 'Questions:', 'Contact Name:', 'Patient eligibility*, test schedule,', 'treatment delays/interruptions/adjustments,', 'dose modifications, adverse events,', 'forms completion and submission', 'Drug administration, infusion pumps,', 'nursing guidelines', 'Forms completion and submission', 'Protocol document, consent form,', 'regulatory issues', 'Serious Adverse Events', '*No waivers of eligibility allowed', 'Protocol Version Date:16Aug2018']['MC1575', '3', 'Amendment 2', 'Table of Contents', 'Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma', '1', 'Protocol Resources', '2', 'Table of Contents', '3', 'SCHEMA', '4', '1.0', 'BACKGROUND', '5', '2.0', 'OBJECTIVES', '14', '3.0', 'ELIGIBILITY', '15', '4.0', 'STUDY CALENDAR', '18', '5.0', 'STRATIFICATION FACTORS: None', '20', '6.0', 'REGISTRATION PROCEDURES', '20', '7.0', 'PROTOCOL TREATMENT', '22', '8.0', 'DOSAGE MODIFICATIONS', '24', '9.0', 'ANCILLARY TREATMENT/SUPPORTIVE CARE', '29', '10.0', 'ADVERSE EVENT (AE) REPORTING AND MONITORING', '32', '11.0', 'TREATMENT EVALUATION', '40', '12.0', 'DESCRIPTIVE FACTORS', '45', '13.0', 'TREATMENT/FOLLOW-UP DECISION AT EVALUATION OF PATIENT', '46', '14.0', 'BODY FLUID BIOSPECIMENS', '47', '15.0', 'DRUG INFORMATION', '48', '16.0', 'STATISTICAL CONSIDERATIONS AND METHODOLOGY', '52', '17.0', 'PATHOLOGY CONSIDERATIONS/TISSUE BIOSPECIMENS', '58', '18.0', 'RECORDS AND DATA COLLECTION PROCEDURES', '60', '19.0', 'BUDGET', '60', '20.0', 'REFERENCES', '61', 'Appendix I', 'ECOG Performance Status', '66', 'Appendix II', 'Patient Medication Diary', '67', 'Appendix III', 'Potential drugs that could interact with lenvatinib (via CYP 3A4)', '69', 'Appendix IV', 'Hypertension Management Guidelines', '70', 'Appendix V', 'Drugs with Risk of Torsades De Pointes', '79', 'Appendix VI', 'Patient Blood Pressure Diary', '80', 'Appendix VII', 'FACT-G (Version 4)', '82', 'Appendix VIII', 'EQ-5D-5L Questionnaire', '84', 'Appendix IX', 'Patient Information Sheet', '87', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}